Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection
Citations Over TimeTop 10% of 2001 papers
Abstract
Entecavir (ETV) is a guanosine nucleoside analogue with potent antiviral efficacy in woodchucks chronically infected with woodchuck hepatitis virus. To explore the consequences of prolonged virus suppression, woodchucks received ETV orally for 8 weeks and then weekly for 12 months. Of the 6 animals withdrawn from therapy and monitored for an additional 28 months, 3 had a sustained antiviral response and had no evidence of hepatocellular carcinoma (HCC). Of the 6 animals that continued on a weekly ETV regimen for an additional 22 months, 4 exhibited serum viral DNA levels near the lower limit of detection for >2 years and had no evidence of HCC. Viral antigens and covalently closed circular DNA levels in liver samples were significantly reduced in all animals. ETV was well tolerated, and there was no evidence of resistant variants. On the basis of historical data, long-term ETV treatment appeared to significantly prolong the life of treated animals and delay the emergence of HCC.
Related Papers
- → The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs(2007)230 cited
- → Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies(1998)117 cited
- → Bioactive Carbocyclic Nucleoside Analogues - Syntheses and Properties of Entecavir(2014)11 cited
- → The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents(2008)2 cited
- → The diagnosis and clinical impact of drug induced, treatment resistant mutations of hepatitis B virus (HBV) during nucleoside analogue therapy(2008)